JP Morgan Healthcare ConferenceJanuary 7-10, 2019San Francisco, CA
Alzheimer’s Association International Conference – ChicagoJuly 22 – 26, 2018Chicago, IL
16th NFXF International Fragile X ConferenceJuly 11 – 15, 2018Cincinnati, OH
2018 SNMMI Annual MeetingJune 23 – 26, 2018Philadelphia, PA
BIO International ConventionJune 4 – 7, 2018Boston, MA
ASENT 2018March 7 – 8, 2018Rockville, MD
NIH Alzheimer’s Research Summit: Path to Treatment and PreventionMarch 1, 2018 & May 24, 2018Bethesda, MD
12th Annual Drug Discovery for Neurodegeneration ConferenceFebruary 4 – 6, 2018Arlington, VA
J.P. Morgan 36th Annual Healthcare ConferenceJanuary 8 – 11, 2018San Francisco
CTAD: Clinical Trials on Alzheimer’s DiseaseNovember 1 – 4, 2017Boston
Alzheimer’s Drug Discovery Foundation Fall SymposiumOctober 27, 2017New York City
West Michigan Medical Innovation SummitOctober 3, 2017MSU College of Human Medicine, Grand Rapids, MI
brainSTEMSeptember 16, 2017Grand Rapids Public Museum
Rodman & Renshaw Investment ConferenceSeptember 10 – 12, 2017New York City
Alzheimer’s Drug Discovery FoundationSeptember 7, 2017New York City
Alzheimer’s Association International ConferenceJuly 16 – 20, 2017London
BIOJune 19 – 22, 2017San Diego


Michigan CelebratesMay 3, 2018Michigan 50 Company to Watch 2018
GRBJDecember 12, 20162016 Newsmaker of the Year finalists
PM360December 21, 2016Innovators 2016: Startups


Crain’s Detroit BusinessMarch 10, 2019Grand Rapids-based Tetra Discovery Partners strikes deal to test Alzheimer’s, Fragile X treatment
FierceBiotech.comDecember 19, 2018Tetra, Shionogi ink $40M pact
MiBizDecember 18, 2018Drug developer Tetra secures $40M investment
GRBJDecember 18, 2018Drug startup inks deal for up to $160M
Endpoints NewsDecember 18, 2018Little Tetra is prepping a PhII Alzheimer’s study. In fact, they just got $40M to fund it.
Rarecast by Global GenesMay 18, 2018Tetra Discovery Partners, building on research about the role the enzyme PDE4 plays in Fragile X.
Michigan Business NetworkMay 8, 2018Michigan 50 Companies to Watch.
Rare Disease ReportApril 3, 2018Fragile X Syndrome Therapy Granted Orphan Drug Designation
WOOD-TV8April 2, 2018GR Company testing autism treatment drug
MI BizApril 1, GR drug developer to test compound as treatment for genetic form of autism
CTAD ConferenceDecember 15, 2017In the Running: Trial Results from CTAD
Spectrum NewsNovember 17, 2017Adult assessment; fragile therapy; neuron nirvana
BioworldNovember 13, 2017Bench Press: AD drug works for Fragile X
DrugTargetReview.comNovember 8, 2017Selective PDE4D inhibitor shows potential to treat Fragile X syndrome 7, 2017Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D)
MedicalResearch.comNovember 7, 2017Novel PDE4 Inhibitor Improves Symptoms of Autism Disorder Fragile X Syndrome in Animal Model
NewYorkSocialDiary.comOctober 31, 2017This past Friday, the Alzheimer’s Drug Discovery Foundation held its 8th annual Fall Symposium & Luncheon at the Pierre.
NeurotherapeuticsApril 12, 2017National Institutes of Health Blueprint Neurotherapeutics Network: Results to Date and Path Forward
FierceBiotechMarch 6, 2017‘Master genes’ may explain why some NFL players develop brain diseases
CEO CFO MagazineJanuary 9, 2017Type 4D Phosphodiesterase (PDE4D) Modulator Currently in Clinical Trials
Life Science LeaderDecember 1, 2016Company Leaders Tackle The New Year’s Toughest Macro Challenges
XconomyNovember 30, 2016Tetra Discovery Raises $10M Series A, Advances Alzheimer’s Drug
GRBJ.comNovember 29, 2016Drug startup secures $10M
MiBizOctober 30, 2016Partner, Sell or IPO? West Michigan life science companies weigh complex next steps
MiBizAugust 5, 2016Tetra Discovery Partners secures $4.28M in VC funding for new drug
GRBJ.comJuly 26, 2016Local drug developer targets traumatic brain injury
FierceBiotech.comJuly 6, 2016Tetra’s experimental med may boost memory after brain injury
MiBizJuly 6, 2016Experimental drug from Tetra Discovery Partners may treat traumatic brain injury
www.rapidgrowthmedia.comMay 26, 2016Making it in Grand Rapids: How the GR Smart Zone is evolving
www.nih.govDecember 30, 2015New NIH-funded memory drug moves into Phase 1 Clinical study
www.BioCentury.comDecember 30, 2015Tetra candidate backed by NIH’s Blueprint enters clinic
MiBizDecember 18, 2015Tetra Discovery to launch clinical trials on Alzheimer’s druge with MPI’s Jasper Clinic
MLive.comDecember 9, 2015Grand Rapids Firm to begin Trials on Alzheimer’s drug that improves memory
www.LifeScienceLeader.comJanuary 29, 2015Tetra Discovery Partners
Xconomy.comOctober 31, 2014Tetra Discovery Partners lands funding
MiBizOctober 26, 2014Financing from Johnson & Johnson Development Corporation and Grand Angels
Grand Rapids Business JournalAugust 22, 2014Additional financing by Grand Angels
Startup: Pharma & MedTech Business IntelligenceDecember 23, 2013
Grand Rapids Business JournalSeptember 30, 2013Initial investment from Grand Angels
MiBizNovember 25, 2012Michigan’s Life Sciences industry on the rise
MLive.comJune 20, 2012NIH Blueprint Therapeutics grant awarded to Tetra Discovery Partners


Tetra Discovery Partners and Shionogi & Co., Ltd. Collaborate on BPN14770 Development and Commercialization

Grand Rapids, MI (December 18, 2018): Tetra Discovery Partners and Shionogi & Co., Ltd. today announced they have entered into a strategic collaboration for the clinical development and commercialization of BPN14770, Tetra’s selective phosphodiesterase-4D (PDE4D) allosteric inhibitor, for the treatment of Fragile X Syndrome, Alzheimer’s disease and other indications marked by cognitive and memory deficits. The goal of the collaboration is to accelerate the development of an innovative therapeutic for patients in key Asian markets. more

Intellectual Property Protection for Tetra Discovery Partners’ BPN14770 Boosted with Issuance of New U.S. Patent

Grand Rapids, MI (October 11, 2018): Tetra Discovery Partners today announced that the U.S. Patent and Trademark Office has issued a third patent covering the company’s selective phosphodiesterase-4D (PDE4D) inhibitor, BPN 14770, and related compounds. The new patent, US 10,093,686, covers claims for the use such compounds in the treatment of mild cognitive impairment, Parkinson’s disease, stroke and ischemia. more

Tetra Discovery Partners Initiates Phase 2 Trial of BPN14770 in Fragile X Syndrome

Grand Rapids, MI (July 10, 2018): Tetra Discovery Partners today announced the initiation of a Phase 2 study of BPN14770 as a potential treatment for Fragile X Syndrome, the most common genetic form of autism. A selective small molecule inhibitor of the phosphodiesterase type-4D (PDE4D) subtype, BPN14770 has shown the ability to improve the quality of connections between neurons and to improve multiple behavioral outcomes in the Fragile X mouse model. BPN14770 has also received Orphan Drug Designation from the U.S. Food and Drug Agency for the treatment of Fragile X Syndrome. more

FDA Grants Orphan Drug Designation for Tetra Discovery Partners’ BPN14770 for the Treatment of Fragile X Syndrome

Grand Rapids, MI (April 3, 2018): Tetra Discovery Partners today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for BPN14770 for the treatment of Fragile X Syndrome. BPN14770 is a selective small molecule inhibitor of the phosphodiesterase type-4D (PDE4D) subtype. Research conducted collaboratively with the FRAXA Research Foundation has shown BPN14770 to improve the quality of connections between neurons and to improve multiple behavioral outcomes in the Fragile X mouse model. more

Tetra Discovery Partners Announces FDA Clearance of IND for Phase 2 Trial of BPN14770 in Fragile X Syndrome

Grand Rapids, MI (March 15, 2018) – Tetra Discovery Partners Inc. (Tetra) today announced that the U.S. Food and Drug Administration has accepted the Investigational New Drug Application (IND) for BPN14770, a novel, selective small molecule inhibitor of the phosphodiesterase type-4D (PDE4D) enzyme, which research suggests may be useful in the treatment of Fragile X Syndrome and possibly other autism spectrum disorders. more

New Preclinical Research Suggests Utility of Tetra Discovery Partners’ BPN14770 to Provide Therapeutic Benefit in Fragile X Syndrome

  • Daily treatment with BPN14770 in a mouse Fragile X model showed reduced hyperarousal, improved social interactions, and improved natural behaviors, as well as changes in neuronal dendrite structure
  • Benefit persisted two weeks after washout of the drug
  • BPN14770 has demonstrated human safety and tolerability in Phase 1 clinical safety study 
  • Research results published online this week in Scientific Reports


Grand Rapids, MI (November 7, 2017) – New preclinical research suggests the potential utility of BPN14770, a selective PDE4D inhibitor currently under development by Tetra Discovery Partners as a prospective treatment for memory and cognitive problems associated with Alzheimer’s disease, in the treatment of Fragile X Syndrome (FXS) and possibly other autism spectrum disorders. more

Tetra Discovery Partners Research Supports Ability of Novel Selective PDE4D Inhibitor, BPN14770, to Improve Memory and Cognition

Grand Rapids, MI (November 6, 2017) – Preclinical, PET imaging, and Phase 1 human clinical evidence supporting the ability of Tetra Discovery Partners’ drug candidate, BPN14770, to improve memory formation and provide cognitive benefit was the subject of an oral presentation on Saturday at the 10th Clinical Trials in Alzheimer’s Disease Meeting held November 1‐4, 2017 in Boston, MA. more

Tetra Discovery Partners Announces Positive Results from Phase 1 Studies of Cognition Drug Candidate, BPN14770

Grand Rapids, MI (December 19, 2016) – Tetra Discovery Partners today announced positive results from two Phase 1 studies of its selective PDE4D allosteric inhibitor drug candidate, BPN14770. The double blind, placebo-controlled, dose-ranging studies were designed primarily to study the safety and pharmacokinetics of single ascending doses and multiple ascending doses of BPN14770 in healthy young and elderly volunteers. more

Tetra Discovery Partners Raises $10 Million through Series A Financing and Two National Institutes of Health Grants — New funds help advance memory drug candidate BPN14770 in Alzheimer’s disease and support Tetra’s development effort in depression

Grand Rapids, MI (November 29, 2016) – Tetra Discovery Partners today announced that it has closed a $5 million Series A Venture Financing. The financing was co-led by the Apjohn Group and Grand Angels, with the participation of previous investors as well as Dolby Family Ventures, the Alzheimer’s Drug Discovery Foundation, and other private investors. With conversion of two debt rounds, the total Series A financing rolls up to $7,277,825.  more

Research from University of Miami and Tetra Discovery Shows Potential of Novel Drug to Improve Memory after Traumatic Brain Injury:  University of Miami Miller School of Medicine / The Miami Project to Cure Paralysis and Tetra Discovery Partners Study Published in the Journal of Neuroscience

Miami, FL – July 6, 2016: Treating rats with an experimental drug at three months following a traumatic brain injury (TBI) improves their learning memory ability, as reported in a new study published online today in the July edition of The Journal of Neuroscience.  The drug, a selective phosphodiesterase 4 subtype inhibitor (PDE4B), is currently under development by Tetra Discovery Partners, a privately held biotechnology company and is being tested as a potential therapy for TBI by University of Miami / Miami Project researchers.  more

Tetra Discovery Partners affirms the significant role Michigan investment offers

Grand Rapids, MI, May 31, 2016:   Dr. Mark E. Gurney, CEO and Chairman of Tetra Discovery Partners LLC, was asked to participate in the Michigan Biosciences Day at the Capitol 2016 in Lansing, Michigan.  MichBIO is the statewide voice of Michigan’s biosciences industry.  During meetings with legislative staff for State Senators Dave Hildenbrand and Margaret O’Brien and State Representative David LaGrand, Dr. Gurney emphasized the importance of state-based investment in early stage biotechnology startups.  Dr. Gurney based his comments on his own experience launching Tetra Discovery Partners in 2011 “with $2,000 in a business checking account,” he said.   more

Tetra Discovery Advances Alzheimer’s Treatment Candidate BPN14770 to Phase I Multiple Ascending Dose Trial

GRAND RAPIDS, MI, April 1, 2016: Tetra Discovery Partners (“Tetra”) today announced that the company has successfully completed its initial Phase 1 single ascending dose (SAD) study of BPN14770 safety in 32 healthy volunteers.  BPN14770 is the company’s experimental treatment aimed at improving memory and slowing the progression of Alzheimer’s disease.  Tetra plans to begin its second Phase 1 trial of BPN14770 in June, which will study multiple ascending doses (MAD).  more

Tetra Discovery Initiates Phase 1 Study of BPN14770, Under Development for Treatment and Prevention of Alzheimer’s Disease

Grand Rapids, MI (December 9, 2015): Tetra Discovery Partners (“Tetra”) today announced that the company has initiated human Phase 1 safety trials of its lead compound BPN14770, which Tetra is developing as a potential treatment to both improve memory and slow the progression of Alzheimer’s disease.   more

Tetra Discovery Partners Announces Additional Financing and Formation of Scientific Advisory Board

GRAND RAPIDS, MI (October 16, 2014): Tetra Discovery Partners (“Tetra”), a drug discovery company developing a portfolio of innovative drugs for psychiatric, neurological and inflammatory diseases, today announced additional private financing. The company has received additional financing from previous seed investor Grand Angels, as well as an investment by Johnson & Johnson Development Corporation (JJDC).

Tetra additionally announced the formation of its Scientific Advisory Board, comprised of four prominent experts in the field of neuroscience and psychiatric drug development:  more

Tetra Discovery to Collaborate with The Broad Institute’s Stanley Center for Psychiatric Research To Pursue Schizophrenia Therapeutics

GRAND RAPIDS, MI (April 9, 2014): Tetra Discovery Partners LLC, a drug discovery company developing a portfolio of innovative drugs for neurological and inflammatory diseases, announced today that the company has entered into a drug development collaboration with the Broad Institute’s Stanley Center for Psychiatric Research in Cambridge, MA. The focus of the collaboration will be to test the potential of Tetra’s drug candidates for improving cognition in the Stanley Center’s proprietary genetic models relating to schizophrenia.  more

Tetra high school intern is semifinalist in the 2014 Intel Science Talent Search

GRAND RAPIDS, MI (January 22, 2014):  Emily D’Amato from Forest Hills Central High School, Grand Rapids, MI was selected as a semi-finalist in the 2014 Intel Science talent Search for her project conducted as an intern at Tetra, “The Development of Phosphodiesterase 4D Inhibitors with 3D Printing and Molecular Visualization Software for the Treatment of Acrodysostosis.”    more

Promising Life Science Start-up Continues Breaking Milestones with Business Assistance & Funding from a Collaboration of MI-based Programs

Grand Rapids, MI – October, 2013 – Leading inventor of Alzheimer’s disease treatments, Dr. Mark Gurney, continues to grow his West Michigan-based lean, biotech start-up – Tetra Discovery Partners, LLC (Tetra) – through the support of a collaboration of Michigan entrepreneurial and funding programs. Tetra is working on the development of three new drugs targeted at improving treatments for Alzheimer’s, depression, and traumatic brain injuries.  more


Latest Financing to Accelerate Development of Alzheimer’s Drug

GRAND RAPIDS, Mich., Sept. 30, 2013 – Tetra Discovery Partners, a leader in the design of new therapeutics for major neurological conditions based on PDE4 modulation in the brain, today announced it has closed a $1,041,000 seed investment led by Grand Angels, a Grand Rapids, Mich.-based investment group.  more